NHS
Bolton
NHS Foundation Trust

**FREEDOM OF INFORMATION**

**REF: 2026-111**
**Subject: Request on the treatment of Mantle Cell Lymphoma (MCL)**

**Dear Sir/Madam,**

Thank you for your email dated **09/02/2026** where you requested information about **Request on the treatment of Mantle Cell Lymphoma (MCL).**

The information you requested is enclosed.

| Question | Answer |
|---|---|
| **Please note time period:** 01/08/2025 - 31/01/2026 | |
| Q1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to? | 27 |
| Q2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments: | |
| • BR (Bendamustine + rituximab) | <10 |
| • VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) | <10 |
| • R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) | <10 |
| • R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) | 0 |
| • CVP (cyclophosphamide, vincristine and prednisolone) | 0 |
| • Brukinsa (zanubrutinib) | 0 |
| • Imbruvica (ibrutinib) | 0 |

| | |
|---|---|
| • Velcade (bortezomib) + chemotherapy | 0 |
| • Tecartus (brexucabtegene autoleucel) | 0 |
| • R-BAC (rituximab, bendamustine and cytarabine) | 0 |
| • R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) | 0 |
| • Any other systemic anti-cancer therapy | 0 |
| • Wait and watch (monitoring only, no active treatment) | <10 |
| Q3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:<br>For this question, please only count patients that have received the below treatments for the first time. | |
| • BR (Bendamustine + rituximab) | <10 |
| • VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) | <10 |
| • R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) | 0 |
| • R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) | 0 |
| • CVP (cyclophosphamide, vincristine and prednisolone) | 0 |
| • Brukinsa (zanubrutinib) | 0 |
| • Imbruvica (ibrutinib) | 0 |
| • Velcade (bortezomib) + chemotherapy | 0 |
| • Tecartus (CAR-T) | 0 |
| • R-BAC (rituximab, bendamustine and cytarabine) | 0 |
| • R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) | 0 |
| • Any other systemic anti-cancer therapy | 0 |
| • Wait and watch (monitoring only, no active treatment) | <10 |

| | |
|---|---|
| Q4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials. | As there have been less than 10 patients treated in the past 6 months we are unable to respond to this query as there is a high risk of re-identification.<br><br>We do not currently have any trials for the treatment of MCL. |

If you have any queries or concerns please do not hesitate to contact the Freedom of Information Department. It would be helpful to quote the above reference number in any future communication.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to The Chief Executive, Bolton NHS Foundation Trust, The Royal Bolton Hospital, Minerva Road, Farnworth, Bolton. BL4 0JR.

If you are not content with the outcome of your complaint you may apply directly to the Information Commissioner. Generally the Information Commissioner cannot make a decision unless you have exhausted the complaints procedure provided by Bolton NHS Foundation Trust. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire. SK9 5AF.

The information supplied to you continues to be protected by the Copyright Design and Patents Act 1998. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication requires the permission of the Trust. You must ensure you gain the Trust permission before reproducing any third party information.

**Yours sincerely,**

**Information Governance Department**

Bolton NHS Foundation Trust
01204 390861
FOI@boltonft.nhs.uk
Informatics Building | Opposite N Block | Royal Bolton Hospital

NHS
Bolton
NHS Foundation Trust

Improving care,
transforming lives...for a better Bolton

Improving care,
transforming lives...for a better Bolton